Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California

Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California

By Venice Servellita, et al. PREPrint ~ August 25, 2021 with Commentary from TrialSiteNews Below Abstract Associations between vaccine breakthrough cases and infection by SARS coronavirus 2 (SARS-CoV-2) variants have remained largely unexplored. Here we analyzed...

read more
Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial

Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial

By Gilmar Reis, et al. PREPRINT August 23, 2021 ABSTRACT Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER randomized platform clinical trial for acutely symptomatic patients with COVID-19, we assessed...

read more

https://www.medrxiv.org/content/10.1101/2021.01.26.21250420v1 Originally published by:  MedRxiv Author: Castaneda-Sabogal et al. Date: 1/26/2021 Categories: Integrative Therapies,Treatment,Ivermectin

read more

https://www.medrxiv.org/content/10.1101/2020.11.30.20236570v1.full Originally published by:  MedRxIV Author: Kalfas, et al. Date: 12/4/2020 Categories: Integrative Therapies,Treatment,Ivermectin

read more

https://www.medrxiv.org/content/10.1101/2020.10.29.20222505v1 Originally published by:  MedRxiv Author: José Morgenstern, et al. Date: 11/1/2020 Categories: Prevention,Integrative Therapies,Treatment,Ivermectin

read more